Dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis).
Last Updated: May 2026
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is currently in Phase 3 clinical development for obesity (SYNCHRONIZE program) and metabolic dysfunction-associated steatohepatitis (MASH), with Phase 2 hepatic and weight-loss data published. Survodutide is not approved for any indication as of May 2026 and is sold as a research-use-only compound by third-party laboratories.
Survodutide activates both GLP-1 and glucagon receptors with a single 39-amino-acid peptide, combining GLP-1-mediated appetite suppression with glucagon-mediated direct energy expenditure and hepatic fat clearance. The glucagon component is the differentiating mechanism — the same axis exploited by retatrutide (triple) and mazdutide (the other Phase 3 dual GLP-1/glucagon, China-led). Half-life is approximately 7 days, enabling once-weekly subcutaneous dosing. Evidence level: Human RCT (Phase 2 published; Phase 3 ongoing).
In a Phase 2 obesity trial (n=387), survodutide produced an average weight loss of 18.7% at the 4.8 mg dose over 46 weeks in adults with overweight or obesity. In a Phase 2 MASH trial, survodutide reduced liver fat content by up to 80% in some participants and produced histological improvement in MASH resolution. The SYNCHRONIZE Phase 3 program in obesity is expected to read out in 2026–2027. Evidence level: Human RCT (Phase 2; Phase 3 pending).
Survodutide and mazdutide share the GLP-1/glucagon dual mechanism but are developed by different sponsors targeting different lead markets — survodutide US/global via Boehringer Ingelheim, mazdutide China-led via Innovent Biologics. Retatrutide adds GIP to that mechanism, producing larger weight-loss signals at the cost of more complex synthesis.
| Compound | Mechanism | Phase 2/3 weight loss | Distinct angle |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon (triple) | 28.7% — TRIUMPH-4 Phase 3, 68 wks | Highest weight loss |
| Survodutide | GLP-1 + glucagon (dual) | 18.7% — Phase 2, 46 wks | MASH liver focus |
| Mazdutide | GLP-1 + glucagon (dual) | 14.4% — GLORY-1 Phase 3, 48 wks | China lead market |
| Tirzepatide | GLP-1 + GIP (dual) | 22.5% — SURMOUNT-1, 72 wks | FDA-approved |
The most common survodutide side effects in Phase 2 were gastrointestinal — nausea, vomiting, decreased appetite — generally mild-to-moderate and concentrated in dose escalation, with discontinuation rates comparable to other GLP-1-class compounds. The glucagon component raises theoretical concerns about heart rate increases that Phase 3 data will further characterize. Long-term safety data is more limited than for FDA-approved alternatives. Evidence level: Human RCT (Phase 2).
Survodutide is not approved by the FDA, EMA, or any other regulator as of May 2026. Boehringer Ingelheim's SYNCHRONIZE Phase 3 program in obesity and parallel Phase 3 program in MASH are expected to support regulatory filings in 2026–2027, with potential approval in 2027–2028. The MASH indication may receive FDA accelerated review given the limited therapeutic options. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Survodutide is among the newer investigational GLP-1/glucagon agonists with a narrower manufacturing base than semaglutide or tirzepatide, creating wider purity variance and stronger economic incentive for underdosing. Independent HPLC purity testing and mass spectrometry identity confirmation are the only meaningful purity signals. Some vendors mislabel survodutide as a generic "GLP-1/glucagon dual agonist" without specifying BI 456906; buyers should confirm the specific compound. Guidance in our how-to-test-peptides hub.
Peptigrity purchases survodutide vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset for what's been tested. Methodology in how we calculate trust scores.
The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay — and for survodutide specifically, buyers should verify the compound is labeled correctly (BI 456906), not as a generic "GLP-1/glucagon dual agonist" that could be mazdutide or another molecule. For COA interpretation, see red flags in peptide certificates of analysis.
Survodutide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Buyers are responsible for verifying local import rules — full breakdown in peptide legal status guide.
No FDA approval has been granted as of May 2026. Boehringer Ingelheim's SYNCHRONIZE Phase 3 program is expected to support an NDA filing in 2026–2027, with FDA approval most plausibly in 2027–2028. The MASH indication may receive accelerated review. Track developments in FDA peptide regulation 2025–2026 timeline.
Yes. Both are dual GLP-1/glucagon receptor agonists with similar mechanism logic but they are different molecules from different sponsors — survodutide (BI 456906) from Boehringer Ingelheim, mazdutide (IBI362) from Innovent Biologics. They are not interchangeable.
No. Survodutide is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. The doses studied in Phase 2 (0.6 mg through 4.8 mg weekly) were administered under clinical supervision. Anyone considering investigational compound use should consult a licensed physician.
Survodutide has produced strong Phase 2 data in MASH (metabolic dysfunction-associated steatohepatitis), with up to 80% reduction in liver fat content in some participants and histological improvement in MASH resolution. The glucagon mechanism is mechanistically suited to hepatic fat clearance — a differentiator from GLP-1-only compounds. A dedicated MASH Phase 3 program is running in parallel with the obesity program.
This section is for educational and informational purposes only and does not constitute medical advice. Survodutide is an investigational compound not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.